InVivoSIM anti-human amyloidbeta (Solanezumab Biosimilar)clone: Solanezumab (Catalog #SIM0047) 

InVivoSIM 抗人類淀粉樣 β（Solanezumab 生物仿制藥）抗體，克?。篠olanezumab（目錄號#SIM0047）

Key features（主要特點(diǎn)）:

1. Solanezumab biosimilar is a humanized IgG1κ antibody against human amyloid-β protein precursor(APP).

2. APP is cleaved into Aβ42 and Aβ40,and Aβ42 drives the formation of neurofibrillary tangles, i.e.,intraneuronal protein clusters, and extracellular Aβ aggregates (senile plaques) causing Alzheimers.

3. Solanezumab binds preferentially with soluble monomers rather than fibrillar beta-amyloid or abeta (i.e., it does not bind Aβ’s aggregated

forms).

4. Solanezumab is shown to promote Aβ clearance from the brain in mouse models. 

1. Solanezumab 生物仿制藥是一種針對人類淀粉樣 β 蛋白前體（APP）的重組人源化 IgG1κ 抗體。

2. APP 被切割成 Aβ42 和 Aβ40，其中 Aβ42 促使神經(jīng)纖維纏結(jié)的形成，即神經(jīng)元內(nèi)蛋白簇和細(xì)胞外Aβ 聚集（老年斑），這會導(dǎo)致阿爾茨海默癥。

3. Solanezumab 優(yōu)先與可溶性單體結(jié)合，而非纖維狀或聚集狀態(tài)的 β淀粉樣蛋白（即它不與 Aβ 的聚集形式結(jié)合）。

4. Solanezumab 已被證明在小鼠模型中促進(jìn) Aβ 從大腦中清除。

Application（應(yīng)用）: in vivo functional assays, in vitro functional assays, ELISA, Western blot, Immunohistochemistry (paraffin)

體內(nèi)功能實(shí)驗(yàn)、體外功能實(shí)驗(yàn)、ELISA、Western blot、免疫組織化學(xué)（石蠟切片）

Research Area（研究領(lǐng)域）: Neuroscience/神經(jīng)科學(xué)

Related targets（相關(guān)靶點(diǎn)）: Amyloid-beta, CD11b,TNF-α, IL-6, IL-3, VEGFR-2 

淀粉樣 β、CD11b、TNF-α、IL-6、IL-3、VEGFR-2 

更多詳情請聯(lián)系 BioXCell 中國授權(quán)一級代理-欣博盛生物科技